kappa -Conotoxin PVIIA Is a Peptide Inhibiting the Shaker K+ Channel*

Ki-Joon ShonDagger , Martin Stocker§, Heinrich Terlau§, Walter Stühmer§, Richard Jacobsen, Craig WalkerDagger , Michelle Grilley, Maren Watkinspar , David R. Hillyardpar , William R. Gray, and Baldomero M. Olivera**

From the Dagger  Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio 44106, § Molekulare Biologie Neuronaler Signale, Max-Planck-Institut für experimentelle Medizin, Hermann-Rein-Strasse 3, D-37075 Göttingen, Germany, and the Departments of  Biology and par  Pathology, University of Utah, Salt Lake City, Utah 84112

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

kappa -Conotoxin PVIIA (kappa -PVIIA), a 27-amino acid toxin from Conus purpurascens venom that inhibits the Shaker potassium channel, was chemically synthesized in a biologically active form. The disulfide connectivity of the peptide was determined. kappa -Conotoxin PVIIA has the following structure.
<AR><R><C>                   <OVL>&cjs0822;                                &cjs0822;</OVL></C></R><R><C><OVL>‖                                        ‖</OVL></C></R><R><C><UP>C<RM>RIONQK</RM>C<RM>FQHLDD</RM>CC<RM>SRK</RM>C<RM>NRFNK</RM>C<RM>V</RM></UP></C></R><R><C><UP>                </UP><UNL><UP><RM>&cjs0822;            </RM></UP></UNL><UP><RM>&cjs0822;</RM></UP></C></R></AR>
<UP><SC>Structure</SC> I</UP>
This is the first Conus peptide known to target K+ channels. Although the Shaker K+ channel is sensitive to kappa -PVIIA, the rat brain Kv1.1 subtype is resistant. Chimeras between Shaker and the Kv1.1 K+ channels were constructed and expressed in Xenopus oocytes. Only channels containing the putative pore-forming region between the fifth and sixth transmembrane domains of Shaker retained toxin sensitivity, indicating that the toxin target site is in this region of the channel. Evidence is presented that kappa -PVIIA interacts with the external tetraethyl-ammonium binding site on the Shaker channel.

Although both kappa -PVIIA and charybdotoxin inhibit the Shaker channel, they must interact differently. The F425G Shaker mutation increases charybdotoxin affinity by 3 orders of magnitude but abolishes kappa -PVIIA sensitivity.

The precursor sequence of kappa -PVIIA was deduced from a cDNA clone, revealing a prepropeptide comprising 72 amino acids. The N-terminal region of the kappa -PVIIA prepropeptide exhibits striking homology to the omega -, µO-, and delta -conotoxins. Thus, at least four pharmacologically distinct superfamilies of Conus peptides belong to the same "O" superfamily, with the omega - and kappa -conotoxins forming one branch, and the delta - and µO-conotoxins forming a second major branch.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The venoms of the 500 species of predatory marine snails belonging to the genus Conus have proven to be a rich source of peptidic ligands with high affinity and specificity. The conotoxins are relatively small, disulfide-bridged peptides (12-30 amino acids) that can readily be chemically synthesized. A large number of peptides that target voltage-gated calcium and sodium channels, as well as the acetylcholine receptor, have been characterized. However, the peptides that target potassium channels in Conus venoms are relatively unexplored; recently, we described an initial characterization of kappa -PVIIA,1 a peptide from the fish-hunting snail Conus purpurascens, which inhibited the Shaker K+ channel but had no effects on any voltage-gated Ca2+ or Na+ channel tested (1). The sequence of kappa -PVIIA bears little apparent homology to the dendrotoxins or to scorpion and spider toxins, which block the Shaker K+ channels.

The Shaker potassium channel is one of the most intensively investigated neuronal signaling macromolecules. Several polypeptide toxins, notably charybdotoxin and the agitoxins (2), have been used to probe this channel; this approach has made the outer vestibule of the Shaker potassium channel the most well mapped region of any ion channel complex. A novel toxin based on a different structural framework from existing ligands could potentially interact with unmapped extracellular regions of the ion channel complex.

In this report, we describe the successful chemical synthesis of kappa -PVIIA and determination of the disulfide connectivity of the biologically active peptide. We have also determined the predicted precursor sequence for the peptide, derived from the nucleic acid sequence of a cDNA clone encoding the peptide. These data confirm the amino acid sequence assignment for kappa -conotoxin PVIIA reported previously (1). Finally, we have investigated interactions between the toxin and chimeric or mutagenized analogs of the Shaker K+ channel.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Native Peptide Purification-- kappa -Conotoxin PVIIA was purified from milked venom obtained as described by Hopkins et al. (3) from specimens of C. purpurascens collected from the Gulf of California. Milked venom was diluted to 10 ml with a solution of 0.1% trifluoroacetic acid, 99.9% H2O and quickly injected onto a C18 Vydac preparative column (22.0 × 250 mm, 10-µm particle size, 300-Å pore size). Elution of peptides was carried out at a flow rate of 20 ml/min, using a gradient of buffer A containing 0.1% trifluoroacetic acid, 99.9% H2O, and buffer B containing 0.085% trifluoroacetic acid, 9.915% H2O, 90% CH3CN as described previously (1). Each peak from the run was collected and stored at 70 °C as stock solutions, and further purification was carried out from these stock fractions. A C18 Vydac analytical column (4.6 × 250 mm, 5-µm particle size) was used for the secondary purification with flow rate of 1 ml/min and B buffer containing 0.085% trifluoroacetic acid, 39.915% H2O, 60% CH3CN.

Partial Reduction and Amino Acid Sequence Analysis-- The stepwise reduction and differential alkylation of kappa -PVIIA to determine disulfide connectivity was carried out as described previously (3-5). The alkylated peptides were purified by HPLC, and sequencing was performed with Edman chemistry on an Applied Biosystems model 477A Protein Sequencer at the Protein/DNA Core Facility at the University of Utah; we are grateful to Dr. Robert Schackmann for the sequence analysis. Mass spectra were measured with a JEOL JMS-HX110 double-focusing spectrometer fitted with a Cs+ gun.

Solid-phase Peptide Synthesis-- The protected peptide resin was built using standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry as described by Shon et al. (4) with two of the cysteines (position 8 and 20) protected by S-acetoamidomethyl and the other cysteines with S-trityl. Other side chains were protected as follows: pentamethylchromasulfonyl (Arg), t-butyl (Hyp, Asp, and Ser), trityl (Asn, His), and t-butoxycarbonyl (Lys). Initially, a two-step oxidation protocol was used to generate three fully disulfide-bonded peptide isomers as detailed by Monje et al. (6); only one isomer was biologically active. This resulted in a very poor yield and led us to try conditions in which the linear peptide without acetamidomethyl-protected Cys was diluted in 0.1% trifluoroacetic acid to less than 50 µM in the presence of 1 mM reduced and 0.5 mM oxidized glutathione (pH adjusted to 7.5). The equilibrium shift induced by the presence of excess reduced glutathione oxidized the peptide to a number of fully oxidized isomers. The major product, which was >90% of this mixture, proved identical to the native peptide (see "Results") and provided a far better yield than the initial two-step oxidation protocol. Five to six hours at the ambient temperature is usually enough to complete the folding reaction using these conditions.

Identification and Sequencing of C. purpurascens cDNA Clones-- 5 µg of venom duct RNA from C. purpurascens was annealed to 3 pmol of a poly(T) oligonucleotide, and cDNA was synthesized by avian myeloblastosis virus reverse transcriptase (5 units; Promega, according to the manufacturer's suggested protocol). The resulting cDNA was used as a template for PCR reaction in 10 10-µl sealed capillary tubes using an Idaho Technology air thermocycler. Each reaction contained 50 ng of template cDNA, 5 pmol each of oligonucleotides corresponding to the 5'- and 3'-untranslated regions sequence of omega -conotoxin prepropeptides, 5 nmol of each of the four dNPTs, and 0.5 units of Taq polymerase (Boehringer Mannheim) in a buffer consisting of 50 mM Tris, pH 8.3, 250 µg/ml bovine serum albumin, and 2 mM MgCl2. The PCR consisted of 40 cycles (94 °C pulse, 54 °C pulse, and 72 °C for 15 s).

The PCR product was gel-purified and recovered from agarose using the Bio-Rad Prep-A-Gene kit according to the manufacturer's protocol. The eluted DNA fragment was ligated to SmaI-digested pUC plasmid pTZ18U by first generating blunt ends (SmaI from Life Technologies, Inc.). The purified PCR product (44 ng) was mixed with SmaI-digested pTZ18U DNA (40 ng) and 0.2 mM of each of the four dNTPs in a buffer containing 25 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 5 mM dithiothreitol, 0.25 mM spermidine, 1 mM ATP, 1.25 mM hexamine cobalt chloride, and 10 µg/ml bovine serum albumin in a final volume of 16 µl. Three units of T4 polymerase (New England Biolabs) were added, and the reaction incubated for 5 min at 37 °C. The enzyme was inactivated by incubation for 15 min at 75 °C and the reaction cooled to 25 °C. Ligation was carried out in the above reaction mixture, to which 3 units of T4 ligase (Promega) and 2 µl of 1 mM ATP were added at room temperature overnight.

Competent DH5alpha F'IQ cells (0.1 ml; Life Technologies, Inc.) were transformed with the entire ligation mix and spread on B agar plates (5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside and isopropyl-1-thio-beta -D-galactopyranoside) containing 50 µg/ml each of ampicillin and kanamycin (all from Sigma). After incubation overnight at 37 °C, colorless colonies produced by recombinant plasmids were screened for the presence of the correct sized insert via PCR with vector-targeting primers in an Idaho Technology air thermocycler. Colonies that contained the correct sized inserts were prepared for DNA sequencing.

Sequencing-- Single-stranded DNA was prepared from putative kappa -PVIIA clones for sequencing by PCR amplification of 50 ng of plasmid with a pair of vector primers, one of which is biotinylated, and binding the resulting PCR product to streptavidin-bound magnetic polystyrene beads (Dynal, Dynabeads M-280 streptavidin). Material for solid-phase sequencing was prepared according to the manufacturer's suggested protocol, generating single-stranded nucleic acid, which was sequenced using the Sequenase version 2.0 DNA sequencing kit, the non-biotinylated vector primer, and [35S]dATP, according to standard Sequenase protocol.

cRNA Synthesis-- Shaker H4 (7) channel gene was cloned in a Bluescript vector. The Kv1.1 (RCK1; Ref. 8) and the chimeras were in pSGEM. Unique restriction sites, which left the primary sequence unchanged, and point mutations were introduced in Shaker and RCK1 channels by PCR mutagenesis, and the amplified sequences were controlled by sequencing. These silent changes added a XbaI site at the coding sequence for Leu186 (after S1), a NheI site at Ala321 (in front of S5), and a DraIII site at Ser390 (beginning of S6) in RCK1. In Shaker, a NheI site was introduced at the corresponding place (Ala391). The new sites, in combination with the available sites, permitted easy replacement of the corresponding Shaker (S) and RCK1 (R) parts to generate the three chimeras (RRS1-4R, RRS5-6R and SSR5-6S). The pSGEM-plasmid with the Kv1.1 channel and the chimeras were linearized with PacI. The Skaker-bearing plasmid was linearized with HindIII. All cDNA clones were transcribed using T7 RNA polymerase.

Oocyte Expression System-- Oocytes from Xenopus laevis were prepared as described previously (9). mRNA was injected into stage V-VI oocytes. Whole cell currents were recorded 1-5 days after injection under two-electrode voltage clamp control using a Turbo-Tec amplifier (NPI Elektronik, Tamm, Germany) driven by the Pulse+PulseFit software package (HEKA Elektronik, Lambrecht, Germany). The intracellular electrodes were filled with 2 M KCl and had a resistance between 0.6 and 1.0 megohms. Current records were sampled at 4 kHz and low pass-filtered at 1 kHz. The bath solution was normal frog Ringer's containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2, 10 Hepes, pH 7.2 (NaOH). Leak and capacitive currents were corrected on-line by using a P/n method. Toxin solution was added to the bath chamber by using a Gilson tip pipette. The indicated toxin concentrations correspond to the final concentration in the bath chamber.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Precursor Sequence of kappa -Conotoxin PVIIA-- A tentative amino acid sequence for kappa -PVIIA was assigned previously (1). An analysis of the purified peptide by mass spectrometry gave a mass (monoisotopic MH+ = 3268.4; theoretical = 3268.42) consistent with the predicted sequence if all Cys residues were disulfide-bonded and the C terminus was not amidated. Both the sequence assignment and the free C terminus were confirmed by chemical synthesis of the peptide (see following section) and by analyzing the sequence of a cDNA clone encoding kappa -conotoxin PVIIA.

The nucleic acid sequence and predicted amino acid sequence of the prepropeptide precursor of kappa -PVIIA is shown in Fig. 1. As is standard for Conus peptides, the 27-amino acid mature toxin is found at the C-terminal end of the 72-amino acid precursor; a typical signal sequence is seen at the N terminus. The stop signal that follows the C-terminal valine confirms that the C terminus is free and not amidated. The proteolytic signal immediately N-terminal to the first amino acid residue (Cys) of the mature peptide, Thr-Arg, is typical of proteolytic signals seen in other Conus peptide precursor sequences.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   The precursor sequence of kappa -conotoxin PVIIA. Nucleotide sequence and inferred amino acid sequence of a kappa -PVIIA-encoding cDNA clone. A cDNA clone from a C. purpurascens cDNA library was identified using PCR as described under "Experimental Procedures."

Chemical Synthesis-- The sequence assignment for kappa -PVIIA and the free C terminus was confirmed by chemical synthesis (see "Experimental Procedures"). The synthetic peptide was biologically active when injected into fish and mice, and proved to have an elution time identical to that for the native material upon high performance liquid chromatography (see Fig. 2). The peptide elicited the same fin-popping syndrome as did native kappa -PVIIA when injected into goldfish, and caused the same hyperactivity syndrome seen with native material when injected intracerebroventricularly into mice. Thus, the successful chemical synthesis of biologically active kappa -conotoxin PVIIA validates the sequence assignment of Terlau et al. (1). The synthesis protocol described routinely yields 5-10 mg of pure peptide.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   Reversed-phase HPLC chromatogram of co-injected natural and synthetic kappa -PVIIA. A 1:1 mixture of natural and synthetic kappa -PVIIA peptides was applied onto a Vydac C18 analytical column and eluted using a 12-30% CH3CN gradient with a flow rate of 1 ml/min, buffer A containing 0.1% trifluoroacetic acid in H2O, and buffer B containing 60% CH3CN, 0.092% trifluoroacetic acid in H2O.

Disulfide Bridging Pattern of kappa -Conotoxin PVIIA-- The disulfide bridge connectivity of kappa -PVIIA was analyzed, using the partial reduction strategy of Gray (10). The spectrum of products obtained after partial reduction using tris(2-carboxyethyl)phosphine is shown in Fig. 3. The partially reduced intermediates (labeled PR1 and PR2 in Fig. 3) were further characterized using the double alkylation strategy described previously (4). Basically, reduced cysteine residues were alkylated using iodoacetamide under rapid alkylation conditions, followed by full reduction and pyridylethylation (using 4-vinylpyridine) of the remaining cysteine residues. The doubly alkylated products were then sequenced for pairwise deduction of the disulfide connectivity.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Reversed phase HPLC chromatogram of partially reduced kappa -conotoxin PVIIA. kappa -PVIIA was partially reduced by 20 mM tris(2-carboxyethyl)phosphine (0.17 M sodium citrate, pH 3.0) at 46 °C for 5 min. Absorbance peaks labeled PR1-PR4 correspond to the partially reduced forms of PVIIA; R corresponds to the fully reduced form, and N to the fully folded form. An analytical C18 Vydac column (4.6 mm × 250 mm) was used for purification; a flow rate of 1 ml/min and a gradient of 1% buffer B increase/min were employed (buffer A, 0.1% trifluoroacetic acid, 99.9% H2O; buffer B, 0.088% trifluoroacetic acid, 45% acetonitrile, 54.912% H2O).

The results of this analysis for two of the partially reduced peptides shown in Fig. 3 provides a consistent data set indicating that the disulfide bridging pattern for kappa -PVIIA is: Cys1-Cys16, Cys8-Cys20, Cys15-Cys26. The disulfide linkage pattern is homologous to that seen for all omega -conotoxins analyzed so far, as well as for the two delta -conotoxins that have been examined, delta -conotoxins TxVIA and GmVIA (4, 11).

Electrophysiological Studies-- A comparison of the activity of kappa -conotoxin PVIIA on the Shaker and rat brain Kvl.1 K+ channels is shown in Fig. 4. The Shaker K+ channel shows fast inactivation, whereas the Kv1.1 channel exhibits non-inactivating currents. It is evident from this figure that, whereas the Shaker K+ channel is sensitive to kappa -conotoxin PVIIA, the cloned Kv1.1 channel from rat brain is not. To define the region of the channel that has the most important determinants for toxin binding, complementary chimeras of the Shaker and Kv1.1 channels were constructed.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   kappa -PVIIA blocks Shaker current but not Kv1.1 currents. Whole cell currents recorded from an oocyte expressing Shaker H4 (left panel) or from an oocyte expressing the Kv1.1 potassium channel (right panel). Voltage steps with a duration of 40 ms ranged from -80 mV to +40 mV in steps of 10 mV and were generated from a holding potential of -100 mV. Addition of 1 µM kappa -conotoxin PVIIA to the bath solution (lower panels) blocks Shaker currents but has no effect on the Kv1.1 currents. The scale bars represent 5 µA.

The chimeric constructs shown (Fig. 5, bottom row) were expressed in oocytes. The effects of kappa -conotoxin PVIIA on these chimeras demonstrate that if the region between S5 and S6 is from the Shaker potassium channel, the resultant hybrid channel is toxin-sensitive. The region between the first four transmembrane domains of the channel protein appears to have little effect on toxin sensitivity; when this domain of Shaker was introduced to the Kv1.1 channel, the chimeric channel remained toxin-insensitive (middle panel). Fast, or N-type, inactivation is dependent on the inactivation particle ("ball") at the N terminus of the Shaker channel. The chimera in Fig. 5 (left panel) containing this N-terminal region is expected to exhibit inactivation. However, this chimera is also toxin-insensitive since it contains the S5-S6 region of Kv1.1 potassium channel. The complementary chimeric channel (Fig. 5, right panel) is non-inactivating (since it has the Kv1.1 N terminus) and toxin-sensitive (since it has the Shaker S5-S6 region). The latter chimeric channel could be more convenient for structure-function and kinetic studies on kappa -PVIIA using electrophysiological techniques than is the original Shaker potassium channel, because the chimeric construct is toxin-sensitive but non-inactivating.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   The S5-S6 loop transfers the sensitivity to kappa -PVIIA. Whole cell currents recorded from oocytes expressing the indicated chimeras between Kv1.1 (R) and Shaker H4 (S). Voltage steps with a duration of 40 ms or 80 ms (RRS5-6R) ranged from -80 mV to +40 mV in steps of 10 mV and were generated from a holding potential of -100 mV. When the S5-S6 loop from Kv1.1 was introduced into the Shaker channel (SSR5-6S), addition of 1 µM kappa -conotoxin PVIIA to the bath solution did not block the currents (left panel). When the S1-S4 part of the Shaker channel was transferred to Kv1.1 (RRS1-4R), the channel was still insensitive to 1 µM kappa -PVIIA (middle panel). When the S5-S6 loop of Shaker was transferred to Kv1.1 (RRS5-6R), the channel became sensitive to kappa -PVIIA (right panel). The scale bars represent 5 µA or 500 nA (RRS5-6R).

Interaction of kappa -Conotoxin PVIIA with the TEA Binding Site on the Shaker Channel-- The Shaker potassium channel is sensitive to external TEA, and mutagenesis has demonstrated that a specific threonine residue, Thr449, is a major determinant in the interaction of the channel with TEA (12). Mutation of the protein at this locus from threonine to tyrosine renders the Shaker K+ channel more TEA-sensitive (12), and makes it resistant to a number of channel-blocking toxins including charybdotoxin (13). Since the experiments on chimeras described above indicated that kappa -PVIIA might be interacting as a channel blocker, we investigated the effects of the T449Y mutation on sensitivity to kappa -PVIIA. As shown in Fig. 6, this mutation does in fact render the channel insensitive to kappa -PVIIA, consistent with the toxin acting as a pore blocker directly interacting with the external TEA binding site. Introducing Lys or Gln in place of Thr449 also resulted in a channel that is insensitive to kappa -PVIIA (data not shown).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   Critical residues for the sensitivity of kappa -PVIIA in the S5-S6 loop. Whole cell currents recorded from oocytes expressing the indicated mutated channel of Shaker H4. Mutating the phenylalanine 425 to glycine (F425G) results in a channel that is insensitive to 1 µM kappa -PVIIA (left panel), whereas with a tyrosine at this position the channel is still sensitive to kappa -PVIIA (middle panel). Mutating the residue threonine at position 449 to tyrosine (T449Y) results in a channel that is insensitive to 1 µM kappa -PVIIA (right panel). Voltage steps were generated as described in Fig. 4. The scale bars represent 2 µA.

kappa -Conotoxin PVIIA and Charybdotoxin Differ in Their Interaction with the Shaker K+ Channel-- Thus far, all evidence presented indicates that kappa -conotoxin PVIIA and charybdotoxin interact very similarly with the Shaker K+ channel. However, in at least one case, the effect of a mutation in the Shaker K+ channel has opposite effects on the two toxins.

It has been shown previously that substitution of the residue Phe425 by glycine increases the affinity of charybdotoxin for the Shaker K+ channel by several orders of magnitude (14). We have assessed the F425G mutation as shown in Fig. 6; in contrast to the strikingly increased affinity of charybdotoxin for the mutant channel, this mutation instead abolishes Shaker potassium channel sensitivity to kappa -conotoxin PVIIA. As a control, we also made the mutation F425Y, a conservative substitution. In contrast to the F425G substitution, the F425Y mutant is still sensitive to 1 µM kappa -conotoxin PVIIA.

Together, these results indicate that both kappa -conotoxin and charybdotoxin generally interact with the pore region between S5 and S6 on the Shaker K+ channel, as well as with the external TEA binding site. However, the effect of the F425G substitution is consistent with different "microsite" interactions (15) for these toxins when binding functionally to the Shaker channel.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The purification and preliminary amino acid sequence assignment for kappa -conotoxin PVIIA has been described by Terlau et al. (1). In this work, we have rigorously established the sequence assignment in three ways: 1) the mass spectrometric analysis yielded a value consistent with the previous sequence assignment; 2) a cDNA encoding kappa -conotoxin PVIIA was identified and sequenced revealing a precursor consistent with the expected amino acid sequence of the mature toxin; and 3) biologically active peptide identical to the natural material was chemically synthesized and folded. The synthetic, oxidized peptide was shown to co-elute with the native material on HPLC. In addition, the three disulfide linkages have been assigned. All the data are consistent with the conclusion that kappa -conotoxin PVIIA shares a common disulfide bridging pattern with the omega - and delta -conotoxins.

The general biochemical features of kappa -conotoxin PVIIA are similar to the omega -conotoxin family of peptides, which block certain subtypes of voltage-gated calcium channels. kappa -Conotoxin PVIIA has the same disulfide pattern as omega -conotoxins and similarly sized intervals between cysteine residues. Furthermore, like the omega -conotoxins, kappa -PVIIA has a large number of positive charges. However, compared with omega -conotoxins as a group, kappa -conotoxin PVIIA has a greater preponderance of hydrophobic residues, as well as a greater number of negative charges leading to a smaller net positive charge.

The prepropeptide sequence of the kappa -conotoxin PVIIA precursor establishes that it belongs to the same superfamily of Conus peptides as do the omega -conotoxins, the delta -conotoxins, and the µO-conotoxins; this superfamily of peptides has previously been referred to as the O superfamily. Apart from the shared disulfide bonding pattern, homology within this Conus peptide superfamily may not be obvious when the individual mature peptide sequences are compared. However, Table I demonstrates that all members of the superfamily share conserved regions in their prepropeptide sequences, particularly in the signal sequence region. A comparison of precursor sequences indicates that the kappa -conotoxins are significantly more closely related to the omega -conotoxins than to the delta - and µO-conotoxins. Thus, there may be two main branches of the O superfamily: peptides targeting K+ and Ca2+ channels (i.e. the kappa - and omega -conotoxins) and peptides that target Na+ channels (i.e. the delta - and µO-conotoxins).

                              
View this table:
[in this window]
[in a new window]
 
Table I
A comparison of O superfamily precursor sequences
The sequence of kappa -conotoxin PVIIA, obtained from C. purpurascens is compared to other precursor sequences of the O superfamily. Both kappa -conotoxin PVIIA and delta -conotoxin PVIA are from C. purpurascens, while omega -conotoxin GVIA is from Conus geographus; both are fish-hunting cone snails. delta -Conotoxin TxVIA and µO-conotoxin MrVIB are from Conus textile and Conus marmoreus, respectively, both snail-hunting species. Note that delta -conotoxin PVIA is much more similar to MrVIB and TxVIA than it is to kappa -conotoxin PVIIA found in the same venom. These results suggest that the two major O superfamily branches were present when fish-hunting and snail-hunting cone snails first diverged from each other. The residues shared by all five peptides are in the boxes with a bold frame, while the residues shared by kappa -PVIIA and omega -GVIA are in finely lined boxes. Note that in the mature toxin region, only the Cys residues are conserved, in contrast to the much higher conservation of signal sequence residues.

The O superfamily of peptides has diverged to the point where individual peptides target all the major classes of voltage-gated ion channels. We note that the delta -conotoxin PVIA precursor, from the same fish-hunting snail as kappa -conotoxin PVIIA, is more closely related to delta - and µO-conotoxin precursors from snail-hunting cones than to kappa -PVIIA found in the same venom. This suggests that the divergence of the two branches of the O superfamily predates the divergence of fish-hunting and snail-hunting cone snails. Although kappa -conotoxin PVIIA is the first potassium channel-targeted toxin so far described from Conus venoms, preliminary results indicate that peptides targeted to potassium channels are likely to be widely distributed among different Conus venoms.2

kappa -Conotoxin PVIIA should be a useful probe for the Shaker potassium channel. We have defined a region that contains the major determinants for kappa -conotoxin PVIIA binding in the Shaker potassium channel complex. For both charybdotoxin and kappa -conotoxin PVIIA, the interaction sites that confer high affinity binding are within the S5-S6 loop (for kappa -PVIIA, see results on chimeras above; for charybdotoxin, see Ref. 2). However, although the two toxins interact with the same general region, there are clearly different microsite interactions. Thus, when Phe425 of Shaker is mutated to a glycine, the KD for block by charybdotoxin increases by over 1000-fold, from 120 nM to about 70 pM (16). In contrast, the same mutation resulted in a channel insensitive to 1 µM kappa -conotoxin PVIIA (see Fig. 6). The effects of the F425G mutation on charybdotoxin were interpreted to be due to a reduction in steric hindrance; the loss of kappa -PVIIA sensitivity by the mutant channel clearly indicates strikingly different interactions with this locus by the two toxins.

The two toxins are similar in their interaction with a residue known to be a strong determinant of external TEA binding, threonine 449 (12). The mutation T449Y results in a channel insensitive to 1 µM kappa -PVIIA. Introducing lysine at the same position (T449K) also results in a channel insensitive to kappa -PVIIA (data not shown). Thus, although the two toxins clearly do not interact with the channel target site in the same way, they may both block functionally important loci for channel function such as the TEA binding site.

The remarkable amount of work that has been done using charybdotoxin as a probe for the Shaker channel serves as a useful paradigm for defining the kappa -conotoxin:Shaker K+ channel complex, as well as for evaluating structural proposals of the outer channel vestibule based on scorpion toxin data. Clearly, an essential requirement before such structure-function work can proceed productively is a determination either by multidimensional NMR techniques or by x-ray crystallography of the three-dimensional structure of kappa -conotoxin PVIIA. Such a structural analysis has been initiated.3

    ACKNOWLEDGEMENTS

We thank M. Kuhnert for help in generating the chimeras, S. Voigt for excellent technical assistance, C. Miller for the clone of Shaker H4, and M. Hollmann for the pSGEM vector.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant PO1 GM48677 (to B. M. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom all correspondence should be addressed: University of Utah, 201 S. Biology, Salt Lake City, UT 84112. Tel.: 801-581-8370; Fax: 801-585-5010.

1 The abbreviations used are: kappa -PVIIA, kappa -conotoxin PVIIA; HPLC, high performance liquid chromatography; PCR, polymerase chain reaction; TEA, tetraethyl-ammonium.

2 H. Terlau, R. Jacobsen, and B. M. Olivera, unpublished results.

3 K.-J. Shon, unpublished results.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Terlau, H., Shon, K., Grilley, M., Stocker, M., Stühmer, W., and Olivera, B. M. (1996) Nature 381, 148-151[CrossRef][Medline] [Order article via Infotrieve]
  2. Miller, C. (1995) Neuron 15, 5-10[Medline] [Order article via Infotrieve]
  3. Hopkins, C., Grilley, M., Miller, C., Shon, K.-J., Cruz, L. J., Gray, W. R., Dykert, J., Rivier, J., Yoshikami, D., Olivera, B. M. (1995) J. Biol. Chem. 270, 22361-22367[Abstract/Free Full Text]
  4. Shon, K.-J., Hasson, A., Spira, M. E., Cruz, L. J., Gray, W. R., Olivera, B. M. (1994) Biochemistry 33, 11420-11425[Medline] [Order article via Infotrieve]
  5. Shon, K., Grilley, M. M., Marsh, M., Yoshikami, D., Hall, A. R., Kurz, B., Gray, W. R., Imperial, J. S., Hillyard, D. R., Olivera, B. M. (1995) Biochemistry 34, 4913-4918[Medline] [Order article via Infotrieve]
  6. Monje, V. D., Haack, J., Naisbitt, S., Miljanich, G., Ramachandran, J., Nasdasdi, L., Olivera, B. M., Hillyard, D. R., Gray, W. R. (1993) Neuropharmacology 32, 1141-1149[CrossRef][Medline] [Order article via Infotrieve]
  7. Kamb, A., Tseng-Crank, Z., and Tanouye, M. A. (1988) Neuron 1, 421-430[Medline] [Order article via Infotrieve]
  8. Stühmer, W., Ruppersberg, J. P., Schröter, K. H., Sakmann, B., Stocker, M., Giese, K. P., Perschke, A., Baumann, A., Pongs, O. (1989) EMBO J. 8, 3235-3244[Abstract]
  9. Stühmer, W. (1992) Methods Enzymol. 207, 319-339[Medline] [Order article via Infotrieve]
  10. Gray, W. R. (1993) Protein Sci. 2, 1732-1748[Abstract/Free Full Text]
  11. Olivera, B. M., Miljanich, G., Ramachandran, J., and Adams, M. E. (1994) Annu. Rev. Biochem. 63, 823-867[CrossRef][Medline] [Order article via Infotrieve]
  12. MacKinnon, R., and Yellen, G. (1990) Science 250, 276-279[Medline] [Order article via Infotrieve]
  13. MacKinnon, R., Heginbotham, L., and Abramson, T. (1990) Neuron 5, 767-771[Medline] [Order article via Infotrieve]
  14. Goldstein, S. A. N., and Miller, C. (1997) Biophys. J. 62, 5-7
  15. Olivera, B. M., Rivier, J., Scott, J. K., Hillyard, D. R., Cruz, L. J. (1991) J. Biol. Chem. 266, 22067-22070[Free Full Text]
  16. Goldstein, S. A. N., Pheasant, D. J., Miller, C. (1994) Neuron 12, 1377-1388[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.